Inhibrx Biosciences, Inc.
INBX
$125.84+11.50 (+10.06%)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
StreetsValue research for Inhibrx Biosciences, Inc. (INBX)
Members get the full report for Inhibrx Biosciences, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.